监测外周血CD34+细胞计数预测普乐沙福联合G-CSF自体干细胞动员的效果

来源期刊：广州医药 | 72-77 发布时间：2024-01-10 收稿时间：2025/11/13 18:28:23 阅读量：52

作者：: 刘芳洁,

宾婷,

谢媚,

解荣丽,

王小博,

关键词：: 造血干细胞动员普乐沙福 CD34+细胞计数; hematopoietic stem cell mobilization plerixafor CD34+cell count

DOI：: 10.3969/j.issn.1000-8535.2023.12.012

收稿时间：: 2023-08-09
修订日期：
接收日期：
引用总数：: 1

目的探讨外周血CD34阳性（CD34⁺）细胞计数对普乐沙福自体干细胞动员效果的预测价值。方法回顾性分析2021年5月—2023年7月中山大学附属第七医院使用人粒细胞集落刺激因子（G-CSF）联合普乐沙福进行自体干细胞动员的13例患者临床资料,分析普乐沙福动员前后外周血CD34⁺细胞计数的变化及干细胞采集情况。结果共有13例患者纳入研究,包括淋巴瘤10例和多发性骨髓瘤3例。多发性骨髓瘤患者中1例为新诊断,另2例为复发患者;淋巴瘤患者中3例为套细胞淋巴瘤,6例为弥漫大B细胞淋巴瘤（包括1例复发）,1例为B细胞淋巴瘤（不能明确类型）。本研究纳入的患者均使用G-CSF动员,在使用普乐沙福后CD34⁺细胞计数均升高,使用普乐沙福前中位CD34⁺细胞计数为13.3（2.5~76.1）/μL,使用普乐沙福后中位CD34⁺细胞计数为73.6（10.4~208.70）/μL,升高4.18（1.99~13.60）倍。13例患者中有2例患者在使用普乐沙福前外周血CD34⁺细胞计数<5 /μL,均动员失败。Spearman相关分析结果显示,使用普乐沙福后CD34⁺细胞计数与使用普乐沙福前CD34⁺细胞数呈正相关（r_s=0.769,P=0.003）。多元线性回归分析显示,使用普乐沙福后CD34⁺细胞计数能较好地预测采集结果（P=0.004）。结论监测外周血CD34⁺细胞计数可预测普乐沙福自体干细胞动员效果,使用普乐沙福后CD34⁺细胞计数越多,CD34⁺细胞采集量越大。

1、钟伟杰,朱志刚.含达雷妥尤单抗方案巩固和维持治疗高龄高危初治多发性骨髓瘤1例并文献复习[J].广州医药,2023,54(2):70-74.

2、许婧钰,严文强,樊慧守,等.硼替佐米联合来那度胺及地塞米松方案对初治多发性骨髓瘤患者的疗效及预后分析[J].中华医学杂志,2022,102(30):2338-2344.

3、周沙,高蕾,高力,等.原发中枢神经系统淋巴瘤的治疗现状及进展[J].白血病·淋巴瘤,2019,28(8):508-512.

4、虞文嫣,任佳逸,糜坚青.多线耐药难治性霍奇金淋巴瘤免疫治疗达完全缓解并成功序贯自体移植1例[J].中国临床案例成果数据库,2022,(1):E7421.

5、邹德慧. 普乐沙福用于动员自体外周血造血干细胞的中国专家共识(2021版)[J].中国肿瘤临床,2021,48(9):433.

6、颜霜,金松,王攀峰,等.VRD方案序贯自体造血干细胞移植治疗新诊断多发性骨髓瘤患者的疗效和安全性研究[J].中华内科杂志,2023,62(7):819-825.

7、 HüBEL K.Mobilization and collection of HSC[M]// The EBMT Handbook.Cham:Springer,2019:117-122.

8、 SWINN T,BUTLER A.Plerixafor use in New Zealand 2016-2019:An observational study[J].Intern Med J,2023,53(6):970-977.

9、 MALINOWSKA I,ROMISZEWSKI M,SMALISZ K,et al.Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience[J].Transfus Apher Sci,2021,60(3):103077.

10、中国医师协会血液科医师分会,中华医学会血液学分会,黄晓军.中国多发性骨髓瘤诊治指南(2022年修订)[J].中华内科杂志,2022,61(5):480-487.

11、 RICARD F,CHESON B,BARRINGTON S,et al.Application of the lugano classification for initial evaluation,staging,and response assessment of Hodgkin and Non-Hodgkin lymphoma:The PRoLoG consensus initiative(Part 1-Clinical)[J].J Nucl Med,2023,64(1):102-108.

12、 COWAN A J,GREEN D J,KWOK M,et al.Diagnosis and management of multiple myeloma:A review[J].JAMA,2022,327(5):464-477.

13、 CHAPPLE P,PRINCE H M,QUINN M,et al.Peripheral blood CD34+ cell count reliably predicts autograft yield[J].Bone Marrow Transplant,1998,22(2):125-130.

14、 ISLAMI M,SOLEIMANIFAR F.A review of evaluating hematopoietic stem cells derived from umbilical cord blood's expansion and homing[J].Curr Stem Cell Res Ther,2020,15(3):250-262.

15、 CHEN J,LAZARUS H M,DAHI P B,et al.Getting blood out of a stone:Identification and management of patients with poor hematopoietic cell mobilization[J].Blood Rev,2021(47):100771.

16、 CREES Z D,RETTING M P,DIPERSIO J F.Innovations in hematopoietic stem-cell mobilization:a review of the novel CXCR4 inhibitor motixafortide[J].Ther Adv Hematol,2023(14):20406207231174304.

17、邹德慧,邱录贵.普乐沙福用于外周血干细胞动员的研究进展[J].中国肿瘤临床,2021,48(11):541-546.

18、 RYBINSK B,RAPOPORT A P,BADROS A Z,et al.Prolonged lenalidomide induction does not significantly impair stem cell collection in multiple myeloma patients mobilized with cyclophosphamide or plerixafor:A report from the covid era[J].Clin Lymphoma Myeloma Leuk,2022,22(8):e716-e729.

19、 THURLAPATI A,ROUBAL K,DAVIS J A,et al.Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy:A real-world experience[J].Transplant Cell Ther,2023,29(5):340.e1-340.e4.

20、 MAZIARZ R T,NADEMANEE A P,MICALLEF I N,et al.Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin Lymphoma and low circulating peripheral blood CD34+ cells[J].Biol Blood Marrow Transplant,2013,19(4):670-675.

21、 KIM J S,YOON D H,PARK S,et al.Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor(G-CSF)in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy:The Korean multicenter retrospective study[J].Ann Hematol,2016,95(4):603-611.

22、 SHAH E,YOUNG R P,WONG S W,et al.Impact of plerixafor use at different peripheral blood CD34+ cell thresholds on autologous stem cell collection in patients with multiple myeloma[J].Biol Blood Marrow Transplant,2018,24(3):S176-S177.

1、王鑫炜.自体造血干细胞化疗动员期间粒细胞缺乏伴发热对动员和植入期感染的影响及植入期感染预防的回顾性研究[D].山西医科大学,2024.DOI:10.27288/d.cnki.gsxyu.2024.000817.